Valuation: Novavax, Inc.

Market Cap 1.33B 1.15B 1.08B 980M 1.84B 127B 1.87B 12.63B 4.94B 63.58B 4.99B 4.88B 211B P/E 2026 *
-12.9x
P/E 2027 * -35.9x
Enterprise Value 1.55B 1.34B 1.26B 1.14B 2.15B 148B 2.18B 14.71B 5.75B 74.07B 5.81B 5.68B 246B EV / Sales 2026 *
4.15x
EV / Sales 2027 * 6.13x
Free-Float
93.05%
Yield 2026 *
-
Yield 2027 * -
1 day-1.11%
1 week+1.26%
Current month+9.97%
1 month-2.31%
3 months-11.15%
6 months-7.47%
Current year+19.79%
1 week 7.78
Extreme 7.78
8.23
1 month 7.15
Extreme 7.15
8.3
Current year 6.76
Extreme 6.76
11.97
1 year 6.2
Extreme 6.2
11.97
3 years 3.53
Extreme 3.5324
23.86
5 years 3.53
Extreme 3.5324
277.8
10 years 3.53
Extreme 3.5324
331.68
Manager TitleAgeSince
Chief Executive Officer 59 2023-01-22
Director of Finance/CFO 60 2021-08-15
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 73 2010-08-05
Director/Board Member 66 2018-10-31
Director/Board Member 60 2020-06-15
Date Insider Type Main position Quantity % Market Cap.
6/20/26 Fiscal year

Director

37,760 0.0230%
6/18/26 Free

Director

35,450 0.0216%
3/1/26 Fiscal year

Chief Financial Officer

275,198 0.1694%
Change 5-day change 1-year change 3-year change Capi.($)
-1.11%+1.26%-15.97%+12.90% 1.33B
-1.78%-1.68%+1.48%+17.26% 48.42B
+0.85%-0.70%+460.88%+581.30% 43.66B
-2.40%-0.23%+8.13%+80.67% 39.51B
-2.01%-0.85%+23.85%+9.97% 38.95B
-0.50%+0.85%+20.60%+58.18% 32.61B
+0.38%-3.23% - - 16.32B
-0.59%-2.06%+26.35%+126.36% 16.15B
+0.49%+0.92%+4.11%+26.37% 14.16B
-0.43%+4.70%+78.74%+38.66% 13.37B
Average -0.71%+0.09%+67.57%+105.74% 26.45B
Weighted average by Cap. -0.92%-0.11%+95.23%+139.58%

Financials

2026 *2027 *
Net sales 373M 322M 303M 275M 518M 35.66B 526M 3.55B 1.39B 17.86B 1.4B 1.37B 59.35B 266M 230M 216M 196M 369M 25.45B 375M 2.53B 990M 12.75B 999M 978M 42.36B
Net income -108M -92.89M -87.29M -79.38M -149M -10.28B -152M -1.02B -400M -5.15B -404M -395M -17.11B -37.93M -32.76M -30.78M -27.99M -52.63M -3.63B -53.5M -361M -141M -1.82B -142M -139M -6.04B
Net Debt 219M 189M 178M 162M 304M 20.94B 309M 2.08B 814M 10.49B 822M 804M 34.85B 303M 262M 246M 224M 421M 28.99B 428M 2.88B 1.13B 14.52B 1.14B 1.11B 48.25B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
26-08-14 US$8.050 -1.11% 2,279,571
26-08-13 US$8.140 +2.26% 3,506,533
26-08-12 US$7.960 +0.13% 2,541,803
26-08-11 US$7.950 +0.76% 2,607,366
26-08-10 US$7.890 -0.75% 3,225,294
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
8.050USD
Average target price
14.00USD
Spread / Average Target
+73.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVAX Stock